Olanzapine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names: Zyprexa, Zydis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Dosing and Administration
Olanzapine should be administered on a once-a-day schedule without regard to meals, generally beginning with 5 to 10 mg initially, with a target dose of 10 mg/day within several days. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 1 week, since steady state for olanzapine would not be achieved for approximately 1 week in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 5 mg QD are recommended.
For information on dosing for Schizophrenia, Mania, or dosing in Special Populations please refer to Instructions for Administration
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Olanzapine
Return to top
Publication Resources
Most Recent Articles on Olanzapine
Review Articles on Olanzapine
Articles on Olanzapine in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Olanzapine
Return to top
Trial Resources
Ongoing Trials with Olanzapine at Clinical Trials.gov
Trial Results with Olanzapine
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Olanzapine
Cochrane Collaboration on Olanzapine
Cost Effectiveness of Olanzapine
Return to top
Media Resources
Powerpoint Slides on Olanzapine
Images of Olanzapine
Podcasts & MP3s on Olanzapine
Videos on Olanzapine
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Olanzapine
Discussion Groups on Olanzapine
Patient Handouts on Olanzapine
Blogs on Olanzapine
Olanzapine in the News
Olanzapine in the Marketplace
Return to top
International Resources
Olanzapine en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
